Literature DB >> 11227093

Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13.

H Avet-Louseau1, A Daviet, S Sauner, R Bataille.   

Abstract

Chromosome 13 abnormalities are frequently observed in multiple myeloma (MM). Several reports recently demonstrated the strong prognostic value of these abnormalities, associated with a short survival. Cytogenetic studies have shown that most of these abnormalities are complete monosomies. In order to define the common minimal deletion, we analysed a series of 234 patients with MM using fluorescence in situ hybridization (FISH) with a panel of five probes mapping along the whole chromosome 13. A chromosome 13 abnormality was observed in 98 patients (42%), 90 of whom (92%) displayed a complete monosomy. In seven of the eight remaining patients presenting partial deletions, the three probes specific for the 13q14 region were deleted. Only one patient (1%) displayed a small deletion of the D13S319 locus. In conclusion, FISH should be used for the analysis of chromosome 13 abnormalities, using probes mapping in the 13q14 region.

Entities:  

Mesh:

Year:  2000        PMID: 11227093     DOI: 10.1046/j.1365-2141.2000.02488.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  18 in total

1.  Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.

Authors:  Laura Chiecchio; Gian Paolo Dagrada; Ashraf H Ibrahim; Elizabet Dachs Cabanas; Rebecca K M Protheroe; David M Stockley; Kim H Orchard; Nicholas C P Cross; Christine J Harrison; Fiona M Ross
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

Review 2.  Genomic complexity of multiple myeloma and its clinical implications.

Authors:  Salomon Manier; Karma Z Salem; Jihye Park; Dan A Landau; Gad Getz; Irene M Ghobrial
Journal:  Nat Rev Clin Oncol       Date:  2016-08-17       Impact factor: 66.675

3.  Increased genomic alteration complexity and telomere shortening in B-CLL cells resistant to radiation-induced apoptosis.

Authors:  H Salin; M Ricoul; L Morat; L Sabatier
Journal:  Cytogenet Genome Res       Date:  2009-01-30       Impact factor: 1.636

4.  Isolation of circulating plasma cells from blood of patients diagnosed with clonal plasma cell disorders using cell selection microfluidics.

Authors:  Joyce W Kamande; Maria A M Lindell; Małgorzata A Witek; Peter M Voorhees; Steven A Soper
Journal:  Integr Biol (Camb)       Date:  2018-02-19       Impact factor: 2.192

Review 5.  Genetic events in the pathogenesis of multiple myeloma.

Authors:  W J Chng; O Glebov; P L Bergsagel; W M Kuehl
Journal:  Best Pract Res Clin Haematol       Date:  2007-12       Impact factor: 3.020

6.  Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myeloma.

Authors:  Julie O'Neal; Feng Gao; Anjum Hassan; Ryan Monahan; Samantha Barrios; Manfred W Kilimann; Ian Lee; Wee J Chng; Ravi Vij; Michael H Tomasson
Journal:  Exp Hematol       Date:  2009-02       Impact factor: 3.084

7.  Evaluation of 13q14 status in multiple myeloma by digital single nucleotide polymorphism technology.

Authors:  Katy Hanlon; Lorna W Harries; Sian Ellard; Claudius E Rudin
Journal:  J Mol Diagn       Date:  2009-07-30       Impact factor: 5.568

Review 8.  Molecular biology of myeloma.

Authors:  N C Gutiérrez; R García-Sanz; J F San Miguel
Journal:  Clin Transl Oncol       Date:  2007-10       Impact factor: 3.405

9.  Deregulation of c-Myc Confers distinct survival requirements for memory B cells, plasma cells, and their progenitors.

Authors:  Sefat E Khuda; William M Loo; Siegfried Janz; Brian Van Ness; Loren D Erickson
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

Review 10.  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

Authors:  R Fonseca; P L Bergsagel; J Drach; J Shaughnessy; N Gutierrez; A K Stewart; G Morgan; B Van Ness; M Chesi; S Minvielle; A Neri; B Barlogie; W M Kuehl; P Liebisch; F Davies; S Chen-Kiang; B G M Durie; R Carrasco; Orhan Sezer; Tony Reiman; Linda Pilarski; H Avet-Loiseau
Journal:  Leukemia       Date:  2009-10-01       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.